Back to Main Story

Patient                            Treatment                Status
Population                         Regimen



Patients with colon           IMC-C225 + irinotecan         Closed
cancer who have failed
other treatments






Patients with locally,        IMC-C225 + cisplatin          Closed
newly diagnosed or            and radiation
recurrent head and
neck cancer






Patients with newly           IMC-C225 + gemcitabine        Closed
diagnosed metastatic
pancreatic cancer






Patients with recurrent       IMC-C226 + cisplatin          Enrolling
or metastatic head and        + 5FU or Taxol                patients
neck cancer






Patients with chemotherapy-   IMC-C225 + carboplatin        Enrolling
nave stage IV non-small-      + paclitaxel                  patients
cell lung cancer






Patients with newly           IMC-C225 + irinotecan         Enrolling
diagnosed stage               + leucovorin + 5-FU           patients
IV colon cancer






Patients with colon           IMC-C225                      Closed
cancer that have failed
other treatments






Patients with                 IMC-C225 + carboplatin        Enrolling
chemotherapy-nave             + gemcitabine                 patients
stage IV non-small-
cell lung cancer






Patients with recurrent or    IMC-C225 + docetaxel          Enrolling
progressive non-small-cell                                  patients
lung cancer






Patients with newly           IMC-C225 + cisplatin or       Enrolling
diagnosed head and            IMC-C225 + placebo            patients
neck cancer with extensive
incurable local-regional
disease and distant
metastases or local-regional
recurrence/persistence or
distant metastases after
initial treatment with surgery
or radiation






Patients with locally         IMC-C225 + radiation          Enrolling
advanced head and neck                                      patients
cancer